

TAKE Solutions Ltd. Announces Results for the Third Quarter ended December 31, 2010

Chennai, India - January 28, 2011

HIGHLIGHTS:

- **Net Profit increased 130% y-o-y and 15% q-o-q**
- **Revenue increased 33% y-o-y and 7% q-o-q**

TAKE Solutions reported consolidated total revenue of INR 1,265 million for the quarter ended December 31, 2010. It represents 33% increase over the same period last year and 7% growth over second quarter of FY 11 ended September 30, 2010.

Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) for the quarter was INR 284 million up 61% y-o-y and 8% q-o-q. Net Profit for the quarter ended December 31, 2010 was INR 189 million. This represents an increase of 130% over the same period last year and 15% over the September, 2010 quarter. The EPS for the quarter was INR 1.58.

<i>All Figures in INR million, except EPS</i>	Q3 FY11	Q-o-Q change (%)	Y-o- Y change (%)	Nine Months ended Dec 31, 2010	FY 10
Total Revenue	1,265	7%	33%	3,548	3,664
EBITDA	284	8%	61%	789	668
Net Profit	189	15%	130%	496	324
Diluted Earnings Per Share (INR)	1.58	15%	131%	4.13	2.70

During the **nine months of FY11** ended December 31, 2010, the company had recorded revenue of INR 3,548 million and net profit of INR 496 million, up 33% and up 145%, respectively, compared to the corresponding period of FY10. For the nine months ended December 31, 2010 EPS was INR 4.13.

BUSINESS OVERVIEW

TAKE had an extremely strong quarter across all businesses and ended the quarter with a strong order book and a solid pipeline of prospects. Our focus on subject matter expertise and thought leadership within Life Sciences only got reinforced with the strategic acquisition of UK based WCI. They are acknowledged leaders in the area of safety, risk, and compliance for bio-pharmaceutical companies and medical device companies and are extending their thought leadership in this area to manufacturers of consumer health products and dietary supplement organizations as well. When combined with TAKE's own deep domain expertise, thought leadership, IP based software solutions, best practices and operational technical excellence; the combined customer base can secure the benefits of a much broader and deeper coverage of the LS and SCM industries.

Life Sciences – Highlights

- Added 7 new customers during the quarter
- Renewed a USD 4 million annual contract with a key life sciences customer
- Signed a USD 2 million contract at a Top 10 large global pharmaceutical major in the area of clinical research – data analysis and aggregation

Supply Chain Management – Highlights

- Added 5 new customers during the quarter
- Signed a USD 2 million SCM software licenses and services contract with a major global conglomerate
- Signed a USD 500,000 SCM software license deal with a major government entity in the US
- Signed a 2 year deal valuing over one million dollar in Middle East with a large CPG company

KEY BALANCE SHEET FIGURES

Particulars	
Book Value Per Share (INR)	24.00
Equity Capital (million)	120
Debtors Days	73 days
Debt (INR million)	1,453
Cash & Cash Equivalents (INR million)	1,787

NEW FACILITY AT 'SHRIRAM - THE GATEWAY'

On October 27, 2010, the new facility of TAKE Solutions at 'Shriram - The Gateway', Perungalathur, Chennai was inaugurated. The facility is spread over 1,18,000 sq ft. This is broken into two phases, the Phase I was commissioned on the same day covering an area of 68,000 sq ft and is capable of accommodating over 650 employees.

Aimed to enhance the scale of operations and expanding the work force, this move further strengthened TAKE Solutions' presence in this region complementing the company's existing office in Chennai.

AWARDS AND RECOGNITIONS

TAKE was selected by Food Logistics for the magazine's annual FL100 list for the fourth consecutive year. TAKE is recognized as a top technology solution provider based on the company's track record of expertise in helping food, beverage and consumer packaged goods (CPG) companies gain competitive advantages through their supply chain and logistics processes. The value that TAKE added to Welch's, Sun Opta, Darigold, and Blue Bell enabled the company's selection in the 2010 FL 100.

M&A ACTIVITY




TAKE Solutions acquires 100% of UK based WCI Consulting Group

In Q3 FY11, TAKE acquired 100% of UK headquartered, WCI Consulting Group through its subsidiary. WCI Consulting is a leading Patient Safety and Compliance advisor to the Life Sciences industry. WCI founded pvnet® and pvconnect®, the industry's primary forum for Patient Safety, which for 10 years have been shaping the industry's approach to pharmacovigilance. With this acquisition, TAKE makes a comprehensive entry into the European Life Sciences market and significantly enhances the Life Sciences domain expertise around pharmacovigilance, risk and compliance.




MAJOR EVENTS ATTENDED

- Oracle's 4th Annual Clinical Development and Safety Conference
- Conference on RFID
- Oracle Health Sciences User Group (UHSUG), 15th Annual Conference
- DIA India: 5th Annual Conference
- CDISC Interchange North America
- PIDX 2010 Fall Meeting
- Webcast: Benefits from an accelerated approach to Oracle R12 from any 11i EBS
- Webcast: DIA Trial Master Reference Model Implementation – Technology Solution

GROWTH TRENDS



Revenue Analysis



CONSOLIDATED PROFIT AND LOSS ACCOUNT FOR THE QUARTER ENDED DECEMBER 31, 2010

All figures are in INR million, except per share data

	Quarter ended		Nine Months ended		Year Ended
	Dec 31, 2010	Dec 31, 2009	Dec 31, 2010	Dec 31, 2009	Mar 31, 2010
Total Income					
Net Sales/Income from Operations	1,249	916	3,507	2,564	3,518
Other Income	15	33	41	99	146
	1,265	948	3,548	2,663	3,664
Expenses					
Cost of Sales	756	605	2,108	1,769	2,354
Other Expenses	225	168	651	423	642
	981	772	2,759	2,192	2,997
Profit Before Interest, Amortization, Depreciation & Tax	284	176	789	471	667
Product Development Expenses Written off	38	53	157	147	180
Depreciation	13	11	33	32	43
Profit before Interest & Tax	233	112	599	292	444
Interest	16	15	36	31	39
Profit before Tax	217	97	563	261	405
Provision for Taxation	22	32	49	39	42
Profit before Minority interest	195	65	514	222	363
Minority interest	6	(18)	18	19	39
Net Profit	189	82	496	202	324
Basic Earnings Per Share (INR)	1.58	0.68	4.13	1.68	2.70
Diluted Earnings Per Share (INR)	1.58	0.68	4.13	1.68	2.70

Earnings Call

The company will conduct a conference call for investors and analysts at **4:00PM, Indian Standard Time (IST) on Friday, January 28, 2011**, where the senior management will discuss the company's performance and answer questions from the participants.

The conference call details are as below:

Conference Access Numbers:

Indian Access Numbers	
Mumbai	(022) 3065 0122/6629 0301
Delhi	(011) 6000 1221
Bangalore	(080) 6000 1221
Chennai	(044) 6000 1221
Hyderabad	(040) 6000 1221

International Access Numbers	
USA Toll Free	001 866 746 2133
UK Toll Free	0 808 101 1573
HK Toll Free	800 964 448
Singapore Toll Free	800 101 2045

Participants are requested to dial-in 10 minutes in advance.

About TAKE Solutions

TAKE Solutions is an international business technology company with products backed by a strong domain expertise in Life Sciences and Supply Chain Management. With extensive technology expertise in Business Intelligence and Business Process Management, TAKE's track record in delivering world-class solutions throughout global markets is well proven. Technological innovations have always been the driving force of the company, which in turn helps TAKE's customers achieve consistent growth in business. Headquartered in Chennai, TAKE primarily drives its SCM Domain Excellence Centre and Global Delivery Centre from India and Middle East. The Company has a strong presence in the USA with the Life Sciences Domain Excellence centre located in Princeton, New Jersey. The Company conducts business today with more than 400 customers worldwide.

TAKE's product suite in the Supply Chain vertical is sold under the umbrella brand 'TAKE Supply Chain', which offers 16 unique products with embedded IP that spans the entire gamut of execution, planning and collaboration. In the Life Sciences domain, IP based software & deep understanding in the functional areas of R&D; commercial applications and operations helps TAKE add tremendous value as a partner. TAKE provides life sciences customers a single source for clinical data services, regulatory-compliant technology solutions and safety data systems.

TAKE is assessed at Level 5 of the Capability Maturity Model Integration (CMMI) & Level 3 of the People Capability Maturity Model (PCMM), Software Engineering Institute, Carnegie Mellon University, USA. TAKE is also a Microsoft Gold Certified Partner, a Business Objects Gold Partner, a Charter Member of the Microsoft BioIT Alliance and along with its subsidiary Applied Clinical Intelligence (ACI), a Registered CDISC Solution Provider, with recognized industry leadership in Microsoft-based Solutions, Regulated Life Sciences, and Supply Chain Management.

More recently, TAKE bagged the Madras Management Association 2010 award for Managerial Excellence in the Services Category. Furthermore, our partnership with large players in the market such as Oracle, SAP, QlikView, Cegedim Relationship Management and Liquent is the recognition of the company's unique offerings.

For more information, please visit www.takesolutions.com.

Disclaimer:

Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in IT including factors which may affect our cost advantage, wage increases, our ability to attract and retain highly skilled professionals, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in SCM & Life Sciences, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our contracts, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. TAKE does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the company.

For more details, please contact:

Sachin Garg

Manager - Investor Relations

Dir: +91 - 44 - 6696 4213

HP: +91- 99625 45467

sachin garg@takesolutions.com

Dhiraj Rajpal / Mayank Vaswani

Citigate Dewe Rogerson

Tel: +91 – 22 – 6645 1241

Tel: +91 – 22 – 6645 1230

dhiraj@cdr-india.com/mayank@cdr-india.com